| Item type |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2013-08-27 |
| タイトル |
|
|
タイトル |
Pharmacokinetics and Safety of Azthreonam in Healthy Japanese Volunteers |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| キーワード |
|
|
主題 |
azthreonam |
| キーワード |
|
|
主題 |
SQ26 |
| キーワード |
|
|
主題 |
776 |
| キーワード |
|
|
主題 |
monobactam |
| キーワード |
|
|
主題 |
healthy Japanese volunteers |
| キーワード |
|
|
主題 |
Phase I |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 著者 |
Nakashima, Mitsuyoshi
Uematsu, Toshihiko
Takiguchi, Yoshiharu
Maeda, Yasuyuki
|
| 書誌情報 |
臨床薬理
巻 16,
号 2,
p. 409-416,
発行日 1985-06-30
|
| 出版者 |
|
|
出版者 |
日本臨床薬理学会 |
| 権利 |
|
|
権利情報 |
Copyright 日本臨床薬理学会 |
| 権利 |
|
|
権利情報 |
本文データは学協会の許諾に基づきJournal archiveから複製したものである |
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Azthreonam (SQ26, 776), a new, completely synthetic, monocyclic β-lactam antimicrobial agent, was administered to 29 healthy, Japanese male volunteers by intravenous bolus infusion, intravenous drip infusion, and intramuscular injection as single doses, and intravenous bolus infusion as multiple dose. The pharmacokinetics of single intravenous doses of 500 mg, 1000 mg and 2000 mg were best described by a linear open two-compartment model. The mean peak serum levels were proportional to the doses but the mean serum half-life was essentially independent of the dose administered (t1/2=1.5-1.8h). The urinary excretion within 24h ranged from 60-70% of the dose administered as intact azthreonam. Usually, intravenous doses were primarily excreted in the 8h urine. The pharmacokinetics of an intramuscular dose of 1000 mg fitted a linear open one compartment model with a mean peak serum level of 66μg/ml at 1h after dosing, and the urinary excretion rate was 80% of the dose administered within 24h. In the multiple dose regimen with 1000 mg of azthreonam administered intravenously to six healthy male subjects every 12h for 5 days, the mean peak serum levels and urinary excretions did not suggest any evidence of drug accumulation. The results of physical examinations and laboratory tests indicated azthreonam was well tolerated with only moderate reversible elevation of CPK values in all subjects at 24h after intramuscular administration. |
| ISSN |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
03881601 |
| EISSN |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
18828272 |
| 著者版フラグ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
JJClinPharTher16_2-409.pdf (791.1 kB)
